行情

VBLT

VBLT

VASCULAR
NASDAQ

实时行情|Nasdaq Last Sale

1.150
-0.020
-1.72%
已收盘, 16:00 11/19 EST
开盘
1.195
昨收
1.170
最高
1.195
最低
1.125
成交量
6.75万
成交额
--
52周最高
1.900
52周最低
0.6000
市值
4,125.97万
市盈率(TTM)
-2.2372
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VBLT 新闻

  • Vascular Biogenics Ltd. VBLT) CEO Dror Harats on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.5天前
  • Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
  • Zacks.5天前
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.5天前
  • VBL Therapeutics Q3 EPS $(0.14), Inline, Sales $79K Miss $120K Estimate
  • Benzinga.5天前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

VBLT 简况

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
展开

Webull提供Vascular Biogenics Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。